A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Ipatasertib
DRUG: Cobimetinib
DRUG: Trastuzumab Emtansine
DRUG: Atezolizumab
DRUG: Bevacizumab
DRUG: Paclitaxel
DRUG: Giredestrant
DRUG: Abemaciclib
DRUG: Inavolisib
DRUG: Palbociclib
DRUG: Letrozole
DRUG: Olaparib
DRUG: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
DRUG: Cyclophosphamide
DRUG: Inavolisib

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]
[object Object]